Single User License
INR 102030
Site License
INR 204060
Corporate User License
INR 306090

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Immunomic Therapeutics, Inc.-Product Pipeline Review-2015

Immunomic Therapeutics, Inc.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Immunomic Therapeutics, Inc.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Immunomic Therapeutics, Inc.-Product Pipeline Review-2015', provides an overview of the Immunomic Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immunomic Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Immunomic Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Immunomic Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Immunomic Therapeutics, Inc.'s pipeline products

Reasons To Buy

Evaluate Immunomic Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Immunomic Therapeutics, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Immunomic Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Immunomic Therapeutics, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immunomic Therapeutics, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Immunomic Therapeutics, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Immunomic Therapeutics, Inc. Snapshot 5

Immunomic Therapeutics, Inc. Overview 5

Key Information 5

Key Facts 5

Immunomic Therapeutics, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

Immunomic Therapeutics, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Combination Treatment Modalities 11

Pipeline Products-Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Immunomic Therapeutics, Inc.-Pipeline Products Glance 14

Immunomic Therapeutics, Inc.-Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Immunomic Therapeutics, Inc.-Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

Immunomic Therapeutics, Inc.-Drug Profiles 18

TriMix-DC Vaccine 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Td+pp65 DC Vaccine 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ASP-4070 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Cell Therapy for HIV 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

EGFRvIII DC Vaccine 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

HIV-LAMP-Vax 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

LAMP-pp65 Dendritic Cell Vaccine + anti-IL-2R Monoclonal Antibody 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

MC-LAMP-Vax 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ARA-LAMP-Vax 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

JCC-LAMP-Vax 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

LAMP + Antigen mRNA Vaccine 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Multi-LAMP-Vax 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Immunomic Therapeutics, Inc.-Pipeline Analysis 32

Immunomic Therapeutics, Inc.-Pipeline Products by Target 32

Immunomic Therapeutics, Inc.-Pipeline Products by Route of Administration 33

Immunomic Therapeutics, Inc.-Pipeline Products by Molecule Type 34

Immunomic Therapeutics, Inc.-Pipeline Products by Mechanism of Action 35

Immunomic Therapeutics, Inc.-Recent Pipeline Updates 36

Immunomic Therapeutics, Inc.-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

Immunomic Therapeutics, Inc., Key Information 5

Immunomic Therapeutics, Inc., Key Facts 5

Immunomic Therapeutics, Inc.-Pipeline by Indication, 2015 8

Immunomic Therapeutics, Inc.-Pipeline by Stage of Development, 2015 9

Immunomic Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 10

Immunomic Therapeutics, Inc.-Combination Treatment Modalities in Pipeline, 2015 11

Immunomic Therapeutics, Inc.-Out-Licensed Products in Pipeline, 2015 12

Immunomic Therapeutics, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 13

Immunomic Therapeutics, Inc.-Phase II, 2015 14

Immunomic Therapeutics, Inc.-Phase I, 2015 15

Immunomic Therapeutics, Inc.-Preclinical, 2015 16

Immunomic Therapeutics, Inc.-Discovery, 2015 17

Immunomic Therapeutics, Inc.-Pipeline by Target, 2015 32

Immunomic Therapeutics, Inc.-Pipeline by Route of Administration, 2015 33

Immunomic Therapeutics, Inc.-Pipeline by Molecule Type, 2015 34

Immunomic Therapeutics, Inc.-Pipeline Products by Mechanism of Action, 2015 35

Immunomic Therapeutics, Inc.-Recent Pipeline Updates, 2015 36

Immunomic Therapeutics, Inc., Other Locations 38

List of Figures

Immunomic Therapeutics, Inc.-Pipeline by Top 10 Indication, 2015 7

Immunomic Therapeutics, Inc.-Pipeline by Stage of Development, 2015 9

Immunomic Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 10

Immunomic Therapeutics, Inc.-Combination Treatment Modalities in Pipeline, 2015 11

Immunomic Therapeutics, Inc.-Out-Licensed Products in Pipeline, 2015 12

Immunomic Therapeutics, Inc.-Pipeline by Top 10 Target, 2015 32

Immunomic Therapeutics, Inc.-Pipeline by Top 10 Route of Administration, 2015 33

Immunomic Therapeutics, Inc.-Pipeline by Top 10 Molecule Type, 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Immunomic Therapeutics, Inc.; Immunomic Therapeutics, Inc. - Key Therapeutics; Immunomic Therapeutics, Inc. - Pipeline Overview and Promising Molecules; Immunomic Therapeutics, Inc. - News; Immunomic Therapeutics, Inc. - Latest Updates; Immunomic Therapeutics, Inc. - Pipeline; Immunomic Therapeutics, Inc. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com